Clinical Trial Update: Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating peginterferon lambda and lonafarnib boosted with ritonavir for chronic Hepatitis Delta has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Hepatitis Delta

Drugs mentioned

• Lonafarnib (lonafarnib)
• Peginterferon lambda-1a (peginterferon lambda-1a)
• Ritonavir (Ritonavir)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Chronic Hepatitis Delta | Phase 2 | Status: WITHDRAWN